Bristol-Myers Squibb Pharma EEIG — China drug registrations and re-registration deadlines
17 certificates in the NMPA overseas-manufactured drug database (境外生产药品库), snapshot 2026-06-28. Earliest re-registration deadline: 2027-07-30.
| Approval number | Product | Certificate expires | Re-registration deadline (Art. 82) |
|---|---|---|---|
| 国药准字HJ20230004 | ZEPOSIA 盐酸奥扎莫德胶囊 | 2028-01-30 | 2027-07-30 |
| 国药准字HJ20230005 | ZEPOSIA 盐酸奥扎莫德胶囊 | 2028-01-30 | 2027-07-30 |
| 国药准字HJ20230006 | ZEPOSIA 盐酸奥扎莫德胶囊 | 2028-01-30 | 2027-07-30 |
| 国药准字SJ20180014 | OPDIVO 纳武利尤单抗注射液 | 2028-03-30 | 2027-09-30 |
| 国药准字SJ20180015 | OPDIVO 纳武利尤单抗注射液 | 2028-03-30 | 2027-09-30 |
| 国药准字SJ20245001 | OPDIVO 纳武利尤单抗注射液 | 2028-03-30 | 2027-09-30 |
| 国药准字HJ20230120 | SOTYKTU 氘可来昔替尼片 | 2028-10-17 | 2028-04-17 |
| 国药准字HJ20171348 | Revlimid 来那度胺胶囊 | 2028-12-06 | 2028-06-06 |
| 国药准字HJ20200046 | Revlimid 来那度胺胶囊 | 2028-12-06 | 2028-06-06 |
| 国药准字HJ20200047 | Revlimid 来那度胺胶囊 | 2028-12-06 | 2028-06-06 |
| 国药准字HJ20200048 | Revlimid 来那度胺胶囊 | 2028-12-06 | 2028-06-06 |
| 国药准字HJ20215003 | Revlimid 来那度胺胶囊 | 2028-12-06 | 2028-06-06 |
| 国药准字HJ20130650 | Abraxane 注射用紫杉醇（白蛋白结合型） | 2028-12-19 | 2028-06-19 |
| 国药准字HJ20160432 | SPRYCEL 达沙替尼片 | 2030-06-11 | 2029-12-11 |
| 国药准字HJ20160433 | SPRYCEL 达沙替尼片 | 2030-06-11 | 2029-12-11 |
| 国药准字HJ20160435 | SPRYCEL 达沙替尼片 | 2030-06-11 | 2029-12-11 |
| 国药准字HJ20160459 | SPRYCEL 达沙替尼片 | 2030-06-11 | 2029-12-11 |
Under the Provisions for Drug Registration (药品注册管理办法) Art. 82, an application to renew an overseas-manufactured drug registration is filed with the Center for Drug Evaluation no later than 6 months before the certificate expires; the filing line column is that arithmetic applied to the expiry cell. Art. 84(1): a certificate with no application by expiry is not re-registered and is cancelled at expiry. Every figure is taken from the public NMPA database as of 2026-06-28, or computed from it. Registration data changes; the NMPA portal governs. This page states no view on whether any of these products' Domestic Responsible Person (境内责任人) arrangements meet NMPA Announcement No. 137 — that cannot be determined from a public entry.